ClinicalTrials.gg
WithdrawnNCT03214835Updated Jul 20, 2020

CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions

An interventional study of Endo CDx Brush biopsy in Laryngeal Disease, Laryngeal Tumor and Laryngopharyngeal Reflux, sponsored by CDx Diagnostics. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-20.

Primary conditionLaryngopharyngeal RefluxRegistry: Laryngeal DiseasesReclassifiedWhy we changed it
Registry
Laryngeal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Laryngopharyngeal Reflux
Why
  1. The study's listed conditions name Laryngopharyngeal Reflux, a narrower term within Laryngeal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CDx Diagnostics · Not applicable, Interventional, and Screening

How we know

Why this study was withdrawn
Study halted prematurely, prior to enrollment of first participant.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study will take place at Rambam medical center, department of Otolaryngology Head and Neck Surgery, for two years. Patients suspected of LPR or laryngeal l tumor and are candidate for laryngeal or hypopharyngeal biopsies will be recruited.

Read the detailed description

First- all patients visiting our clinic with laryngeal complaints suspicious for either LPR or laryngeal tumor will fill the RSI questionnaire. Then fiberoptic examination will be performed by a laryngologist that will complete the RFS score.

Patients with suspicious lesions will be referred for TFL standard biopsy and CDx brush biopsy in order to determine whether the lesions are malignant or benign. The pathologic diagnosis of invasive carcinoma from a TFL biopsy is considered equivalent to the pathology results from a direct laryngoscopy biopsy. All patients with benign pathology or carcinoma in-situ (CIS) on TFL biopsy will be referred for subsequent direct laryngoscopy (DL) for definitive diagnosis. At the time of the DL biopsy will include also another CDx brush smear. Patients with benign-appearing lesions will be taken for lesion removal and biopsy.Before removal of the lesion a CDx brush smear will be collected.

All the participants suspected of LPR will have: PHmetry with Manometry andCDx brush biopsy.All relevant demographic and clinical data will be retrieved for analysis.

CDx biopsies will be an addition to the routine management of the patients in the diagnosis and follow-up of laryngeal lesions and LPR and will not replace the standard regimen.

02

Conditions studied

  • Laryngeal Disease
  • Laryngeal Tumor
  • Laryngopharyngeal Reflux

Keywords

  • Larynx
  • reflux
  • LPR
  • tumor
  • lesion
03

In context

Laryngopharyngeal Reflux Reclassified

56 studies on the registry are indexed under Laryngopharyngeal Reflux; 8 are open to participants now.

Browse Laryngopharyngeal Reflux studies →

Lead sponsor

CDx Diagnostics is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Laryngopharyngeal Reflux, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Laryngeal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or over
  • patients suspected to suffer from LPR
  • Patients with laryngeal/hypopharyngeal lesions.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Patients with anatomical variants which precludes taking.
  • Patients with allergy to lidocain-based local anesthesia agents.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Brush biopsy for laryngeal lesion

    Brush biopsy of the larynx - in addition to the standard biopsy

    Device: Endo CDx Brush biopsy

  • Experimental
    Brush biopsy for LPR

    Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)

    Device: Endo CDx Brush biopsy

Interventions

  • DeviceEndo CDx Brush biopsy

    In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.

06

What researchers measure

Primary outcomes

  1. Efficacy of EndoCDx brush

    Efficacy of EndoCDx brush biopsy as a diagnostic tool for laryngeal lesions compared to cup forceps biopsy and a diagnostic tool for LPR compared to double probe PH monitoring

    Time frame: 3 months

Secondary outcomes

  1. Assessment of pain

    Assessment of pain during EndoCDx brush biopsy under local anesthesia by Visual Analog Score for pain

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2018; primary completion for Aug 2019, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2017
First posted
Jul 12, 2017
StartEst.
Feb 1, 2018
Primary completionEst.
Aug 2019
CompletionEst.
Dec 2019
Last update
Jul 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03214835
Lead sponsor
CDx Diagnostics
Responsible party
Sponsor
First posted
Jul 12, 2017
Start date
Feb 1, 2018 (estimated)
Primary completion
Aug 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Jul 20, 2020

Study contacts

Jacob Cohen, MD
principal investigator · Rambam Health Care Campus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion